48 results about "Methadone" patented technology

This invention relates to a method of selectively enhancing the analgesic potency of morphine and other clinically used bimodally-acting opioid agonists and simultaneously attenuating development of physical dependence, tolerance and other undesirable side effects caused by the chronic administration of said bimodally-acting opioid agonists comprising the co-administration of a bimodally-acting opioid agonist which activates both inhibitory and excitatory opioid receptor-mediated functions of neurons in the nociceptive (pain) pathways of the nervous system and an opioid receptor antagonist which selectively inactivates excitatory opioid receptor-mediated side effects. This invention also relates to a method of using excitatory opioid receptor antagonists alone to block the undesirable excitatory side effects of endogenous bimodally-acting opioid agonists which may be markedly elevated during chronic pain. This invention further relates to a method of long-term treatment of previously detoxified opiate, cocaine and alcohol addicts utilizing said excitatory opioid receptor antagonists, either alone or in combination with low-dose methadone, to prevent protracted physical dependence, and to compositions comprising an excitatory opioid receptor antagonist of the invention and a bimodally-acting opioid agonist.

Methods and compositions are provided for administering methadone to a subject. Aspects of the invention include employing a topical methadone formulation, e.g., a patch or analogous topical administration formulation. The subject methods and compositions find use in a variety of applications, e.g., in the treatment of a variety of different types of pain.

A pharmaceutical composition comprising an analgesic or analgesic combination and a stool softener is disclosed. The analgesic is selected from morphine, meperidine, fentanyl, hydromorphone, oxymorphone, oxycodone, hydrocodone, methadone, propoxyphene, pentazocine, levorphanol, codeine, acetaminophen and combinations of these analgesics. The composition is formulated for oral administration as a liquid or solid dosage form for immediate, slow, delayed or sustained-release characteristics.

An injectable slow-release partial opioid agonist or opioid antagonist formulation is provided comprising a partial opioid agonist or opioid antagonist in a poly(D,L-lactide) excipient with a small amount of residual ethyl acetate. Upon intramuscular injection of the composition, a partial opioid agonist or opioid antagonist is released in a controlled manner over an extended period of time. The composition finds use in the treatment of heroin addicts and alcoholics to reduce consumption of the abused substances. Of particular interest are the drugs buprenorphine, methadone and naltrexone.

The invention belongs to the technical field of analytical chemistry, and relates to a method for rapidly assaying four amphetamines (amphetamine, methamphetamine, methylene-dioxy-amphetamine and methylene-dioxy-methamphetamine), ketamine, pethidine and methadone in blood and urine. The method is high in sensitivity and specificity and wide in linear range, can be used for qualitatively and quantitatively assaying analytes of unknown concentrations in the blood and the urine, and is simple and rapid to operate; according to the method, processes of extracting, and drying by evaporating are not required, and characteristics that a judicial expertise task is urgent and has a high requirement on assaying time can be met; an assaying system, provided by the invention, provides a new technical platform for drug assaying, and is easy to popularize and apply.

A short treatment with noribogaine shows promise for treating drug dependency. Many opioid addicts are treated with methadone. Giving noribogaine to mammal concurrently being administered methadone surprisingly exacerbates methadone's negative side-effects, and increases the risk of death. Therefore, prior to noribogaine treatment, a patient on methadone therapy undergoes a period of methadone abstinence to wash out the methadone. Surprisingly, noribogaine does not react negatively to morphine. According to the invention, methadone regimen is replaced with morphine prior to noribogaine treatment.

The invention belongs to the technical field of drug detection and judicial identification, and in particular relates to the detection of seven abused drugs amphetamine, methamphetamine, methylenedioxyamphetamine, methylenedioxy The method for extracting and measuring methamphetamine, ketamine, pethidine and methadone uses methanol as a dispersant and a protein precipitation solvent, uses dichloromethane as an extraction solvent, and forms a microemulsion system of a three-solvent system in an aqueous solution of pH 13, With the assistance of ultrasound, it is further emulsified for liquid-liquid microextraction, and the extraction process does not need to evaporate the extraction solvent; this method has high enrichment multiple and recovery rate, simple and fast operation, high sensitivity, strong specificity, wide linear range and It has the advantages of low cost and environmental friendliness, and can meet the characteristics of urgent judicial appraisal tasks and high requirements for detection time. The detection system of the invention provides a new technical platform for drug detection.

A pharmaceutical composition comprising an analgesic or analgesic combination and a stool softener is disclosed. The analgesic is selected from morphine, meperidine, fentanyl, hydromorphone, oxymorphone, oxycodone, hydrocodone, methadone, propoxyphene, pentazocine, levorphanol, codeine, acetaminophen and combinations of these analgesics. The composition is formulated for oral administration as a liquid or solid dosage form for immediate, slow, delayed or sustained-release characteristics.

A methadone self-service medicine taking method, a medicine taking machine and a management system are realized based on a self-service medicine taking machine, and the method comprises the followingsteps: 1) collecting and verifying user information; 2) after the verification is passed, discharging a medicine cup by the self-service medicine taking machine; (3) when the user takes the medicine cup, identifying the action of the user and judging whether the user executes the medicine taking action or not by the self-service medicine taking machine; if so, entering step 4) and if not, enteringstep 5); (4) collecting user voice information and judging whether medicine taking is completed or not by the self-service medicine taking machine, if not, entering the step 5), and if yes, ending the operation; (5) reminding people of exception and recording the exception by the self-service medicine taking machine. The standardization of special medicine can be achieved, labor cost is effectively reduced, and resource utilization rate maximization and intelligent management are achieved.

Highly efficient methods for synthesis of levomethadone hydrochloride or dextromethadone hydrochloride are provided starting from D-alanine, or L-alanine, respectively, with retention of configuration. Methods for treating a subject are provided comprising administering a composition comprising an effective amount of levomethadone hydrochloride having not more than 10 ppm dextromethadone.

The invention discloses a low-frequency therapeutic apparatus for drug detoxification, which is regulated and controlled by a computer and is equipment for the drug detoxification and solves the problem of poor effects of healing with drugs for the drug detoxification in the past. The low-frequency therapeutic apparatus for the drug detoxification, regulated and controlled by the computer, comprises a power source and a shell, the shell is internally provided with a controller and the input end of the controller is connected with the computer while the output end of the controller is connected with a therapeutic electrode. By virtue a method of acupuncture points and meridians in the traditional Chinese medical science, a pulse signal generated by the driving of the controller by the computer passes through the therapeutic electrode and a skin electric shocking pulse is directly adopted to stimulate acupuncture points of a human body for treatment, thus promoting the releasing of enkephalin in the human body, further relieving the withdrawal symptoms of opiate narcotics and having the effects of pain easing and spasmolysis and better withdrawal effect than amidone methadone. The therapeutic apparatus of the invention has safe and reliable application, no pain, no side effect, and obvious effects for relieving addiction and controlling relapse. The computer is used for regulating and controlling so as to realize simple operation and accurate curative effect.

The invention discloses a methadone hapten, a preparation method of the methadone hapten, a methadone antigen, a methadone monoclonal antibody and application of the methadone monoclonal antibody. The methadone hapten has a structure represented by a formula I shown in a drawing; according to the preparation method of the methadone hapten, methadone is reduced into hydroxyl methadone, the hydroxyl methadone is subjected to esterification reaction with succinic anhydride, and then, the methadone hapten is prepared; the methadone antigen is prepared through connecting the methadone hapten with a protein carrier; the methadone monoclonal antibody is prepared through applying the methadone antigen to an animal for immunization and then using a hybridoma technique or DNA (Deoxyribonucleic Acid) recombination method; and the methadone monoclonal antibody is applied to the preparation of reagents, reagent strips or kits for detecting samples. The methadone hapten, the methadone antigen and the methadone monoclonal antibody have the advantages that the antigen disclosed by the invention has high immunogenicity, and the immunoreactivity of methadone is preserved; the methadone monoclonal antibody is excellent in specificity and high in potency; and a colloidal gold-labeled methadone monoclonal antibody immunological test strip is high in sensitivity and strong in specificity, is simple, convenient and quick, and can be applied to site detection, and the like.

A pharmaceutical composition comprising an analgesic or analgesic combination and a stool softener is disclosed. The analgesic is selected from morphine, meperidine, fentanyl, hydromorphone, oxymorphone, oxycodone, hydrocodone, methadone, propoxyphene, pentazocine, levorphanol, codeine, acetaminophen and combinations of these analgesics. The composition is formulated for oral administration as a liquid or solid dosage form for immediate, slow, delayed or sustained-release characteristics.

The invention discloses a method for fast detecting Fluorine both Otunnu methadone drug residue, which uses biology immune technology and cattle blood albumin as carrier protein, then it combines the Fluorine both Otunnu methadone drug to prepare the corresponding peculiarity antibody; it fixes the prepared peculiarity antibody on the piezo-crystal surface to form biology identify unit; it prepares the tested Fluorine both Otunnu methadone drug standard solution with series intensity and then puts the biology identifying unit into the solution to do fully reaction and detects the frequency; it establishes standard curve according to the frequency differential and the linear relation of the tested content; it obtains the frequency differential by making the biology identifying unit to fully react with the unknown extracting liquid; then it computes the content of the Fluorine both Otunnu methadone drug of the unknown sample by the standard curve.

The invention relates to the technical field of robots, and discloses a methadone self-service medicine taking robot and a using method and a control method thereof, the methadone self-service medicine taking robot comprises a machine body, and the machine body comprises a medicine taking hole, a hand detection module, an identification module, a man-machine interaction module, a control module, a cup conveying and recycling device, a medicine supply device and an automatic paper cup supply device. Through cooperative work of all devices and modules of the methadone self-service medicine taking robot and the corresponding use and control method, perfect self-service medicine taking service can be provided for treatment personnel, the mode that management personnel distribute methadone liquid medicine to the treatment personnel is replaced, the treatment personnel can be supervised to completely take the liquid medicine, and the treatment efficiency is improved, and the purpose of reducing the labor cost required by the operation of the methadone treatment station is achieved.

Methadone is a frequently employed agent for the treatment of drug addiction and the treatment of pain. Methadone prolongs the cardiac action potential, which on the surface electrocardiogram is represented by QT prolongation. This QT prolongation is known to increase the risk for the development of cardiac arrhythmias, especially the form of ventricular tachycardia known as Torsade de Pointes. For this reason, the FDA has inserted a “black box” warning for potential life threatening arrhythmias. The invention described in this application is the surprising finding that the R-isomer of methadone causes less inhibition of the potassium channel, IKr and thus would have less of a chance of causing life threatening arrhythmias. What is claimed is a method of chirally separating methadone with one isomer having less QT prolongation and more analgesic action that would make a superior pharmacologic agent than the racemate R,S methadone.

The present invention is aimed at providing an opioid antagonist compound and preparation method thereof, and its medical use. The medical use for opioid antagonists such as the compound of formula (I) (shown below) include complete or partial reversal of narcotic depression, including respiratory depression, induced by opioids including natural and synthetic narcotics, such as heroin, fentanyl, oxycodone, hydrocodone, morphine, propoxyphene, methadone and certain narcotic-antagonist analgesics, such as nalbuphine, pentazocine and butorphanol. An opioid antagonist may also be useful as an adjunctive agent to increase blood pressure in the management of septic shock. Further, opioid antagonists also have been shown to reduce the craving for alcohol.

A method for the detection and quantitation of pain medication in oral fluid specimens is provided. First, a Solid Phase Extraction (“SPE”) process is used to isolate cocaine and its metabolite, amphetamines and / or butalbital from human oral fluid samples. Alternatively, Liquid-Liquid Extraction (“LLE”) is used to isolate methadone and its metabolite, fentanyl and norfentanyl, buprenorphine and norbuprenorphine, propoxyphene and norpropoxyphene, carisoprodol, meprobamate, a series of benzodiazepines, tramadol and its metabolites, the analgesic opioids, and tetrahydrocannabinol (“THC”) and its carboxylated metabolite (“THC-C”). Finally, following isolation of these drugs and their metabolites, they are separated respectively using a high performance liquid chromatographic column and a novel combination chromatographic solvents and gradients. All analytes are detected and quantified using a tandem mass spectrometry (“MS / MS”) precursor to produce ion transitions.

Provided is a drug substance and a method of treating an ailment comprising administering an oral dose of a drug product comprising the drug substance wherein the drug substance comprises an organic acid addition salt of methadone. The organic acid addition salt is selected from the group consisting of pamoate and xinafoate wherein the drug substance is bioavailable under gastrointestinal administration but is not bioavailable under administration at a mucosal membrane other than gastrointestinal or release from a depot injectable product.

Mixed inhibitors of aminopeptidase N and of neprilysine are described. Pharmaceutical compositions containing at least one of these compounds, used alone or in combination with morphine and derivatives thereof, endocannabinoids and inhibitors of the metabolism thereof, GABA derivatives such as gabapentin or pregabalin, duloxetine or methadone, can be used as an analgesic, anxiolytic, antidepressant or anti-inflammatory.

The embodiments herein provide a nano-carrier system for delivering a long-acting injectable drug of methadone and a method of synthesising the same. The methadone entrapped nanoparticles are prepared using a lipid / phospholipid core which is coated by a polymer. The lipid and phospholipid are dissolved in organic solvent. This solution is transferred into an aqueous phase consisting of distilled water or a buffer. A solution of polymer is added drop wise. The drug entrapped nanoparticle formation is achieved by diffusion of the organic solvent within the aqueous solvent to obtain the nanoparticles. The drug gets entrapped within the nanoparticles via the anti-solvency effect of the aqueous matrix. The resulting drug nanocarriers are capable of releasing the drug in a slow rate upon injection. The synthesized drug carrying nanoparticles are cryopreserved stored for future administration. For better storage, the nanodispersion is dried to form a powder.

The invention provides a methadone drug maintenance treatment self-service station networking management system, which comprises a methadone drug maintenance treatment self-service station cloud platform and a methadone drug maintenance treatment self-service station, wherein the methadone drug maintenance treatment self-service station comprises an access control identification module, a region monitoring module and a methadone drug maintenance treatment self-service machine, the methadone drug maintenance treatment self-service station is controlled by the methadone drug maintenance treatment self-service station cloud platform. The methadone drug maintenance treatment self-service station networking management system realizes the functions of self-service taking, safety management, doserecording and the like of methadone drugs, enhances the drug using safety and convenience, and can obtain a large amount of clinical data through continuously recording of the drug dose, so as to facilitate the conduction of health evaluation of methadone drug maintenance treatment personnel, further facilitate the supervision of methadone drug maintenance treatment personnel by the public security department, carries out research and development from the three perspectives of intelligent photographing, user attitude judgment and drug container attitude adjustment, and improves the drug taking comfort of the user.

Non-racemic mixtures of D- and L-methadone containing a ratio ranging from about 2.5:1 to about 3.5:1 by weight of D-methadone to L-methadone, such as for example about 2.9:1 to about 3.1:1 by weight of D-methadone to L-methadone, or about 3:1 by weight of D-methadone to L-methadone, have been found to exhibit surprising and unexpected beneficial results in the treatment of neuropathic pain. Additionally, non-racemic mixtures of D- and L-methadone containing a ratio ranging from about 2.5:1 to about 3.5:1 by weight of D-methadone to L-methadone, about 2.9:1 to about 3.1:1 by weight of D-methadone to L-methadone, or for example about 3:1 by weight of D-methadone to L-methadone, in combination with other non-methadone opioids have been found to exhibit surprising and unexpected beneficial results in the treatment of mixed pain.

The invention relates to the field of robot technology, and discloses a methadone self-service medicine robot and its use method and control method. Cup and recovery device, medicine supply device and automatic paper cup supply device. Through the cooperative work of each device and module of the methadone self-administration robot and the corresponding use and control methods, it can provide complete self-medication service for the treatment personnel, replace the way that the management personnel distributes methadone liquid medicine to the treatment personnel, and can supervise the treatment personnel to use The liquid medicine is completely taken to achieve the purpose of reducing the labor cost required for the operation of the methadone treatment station.

The present invention relates to pharmaceutical compositions and methods wherein L-methadone and at least one other opioid analgesic are administered in amounts effective to potentiate a synergistic antinociceptive response to moderate and severe pain, preferably with decreased dependence and tolerance potential. Synergistic potentiation of analgesia through administration of pharmaceutical compositions comprising L-methadone and at least one other opioid analgesic provides a new and improved approach to pain management.

The invention relates to compounds that demonstrate efficacy in blocking PACAP receptors (e.g. PAC1) and associated methods of treating neurological diseases or disorders using the disclosed compounds. The neurological diseases or disorders include, but are not limited to, stress-related diseases (e.g. chronic stress, post-traumatic stress disorder (PTSD), anxiety, or general anxiety disorder), pain-related diseases (e.g. chronic pain, primary headache disorders, or migraines), or addiction (e.g. addiction to a substance (e.g. addiction to cocaine, amphetamines, methamphetamine, methylphenidate, nicotine, alcohol, prescription medication, marijuana, tobacco, or an opioid selected from heroin, fentanyl, codeine, hydrocodone, morphine, oxycodone, hydromorphone, and methadone)).

The embodiments herein provide a nano-carrier system for delivering a long-acting injectable drug of methadone and a method of synthesizing the same. The methadone entrapped nanoparticles are prepared using a lipid / phospholipid core which is coated by a polymer. The lipid and phospholipid are dissolved in organic solvent. This solution is transferred into an aqueous phase consisting of distilled water or a buffer. A solution of polymer is added drop wise. The drug entrapped nanoparticle formation is achieved by diffusion of the organic solvent within the aqueous solvent to obtain the nanoparticles. The drug gets entrapped within the nanoparticles via the anti-solvency effect of the aqueous matrix. The resulting drug nanocarriers are capable of releasing the drug in a slow rate upon injection. The synthesized drug carrying nanoparticles are cryopreserved stored for future administration. For better storage, the nanodispersion is dried to form a powder.

The invention discloses a medicine quantity control method and a methadone medicine drinking machine. The methadone medicine drinking machine comprises an identity recognition module, a language prompt module, an image acquisition module, a weighing module, a constant temperature heating module, a medicine input module, two medicine quantity detection modules and a touch display module. The medicine quantity control method comprises the following steps: S1, identity recognition; S2, data calling; S3, medicine quantity distribution; S4, weight monitoring; and S5, final detection; through cooperation of equipment, during utilization, an actual required medicine taking quantity of a user is judged through the identity recognition, in addition, the medicine quantity is distributed in real time through the medicine quantity distribution, the correct input quantity of the medicine quantity of the user is guaranteed, the situation that the medicine quantity is insufficient or excessive is prevented, and in the use process, through a weighing module arranged on an operation table, a simple detection for the medicine taking condition of the user during use is greatly increased, and the situation that the medicine taking quantity of the user is insufficient during use is prevented.